Video: CSL Behring Provides $1.2M Grant for World's First Study of Postpartum Women with VWD, Common Bleedin...(tted to improving the quality of life fo...)

Date:8/18/2008

tted to improving the quality of life for people with rare and serious diseases," said Robert Lefebvre, General Manager and Vice President of U.S. Commercial Operations at CSL Behring. "We hope that CSL Behring's support of this groundbreaking study will enable researchers to produce results that clinicians around the world can use in treating women who have VWD after they give birth."

In all women, von Willebrand factor (VWF) and factor VIII (FVIII) levels increase throughout the third trimester and then decrease to baseline within one month postpartum. There is anecdotal evidence that in women with VWD, this physiologic postpartum decrease in VWF and FVIII levels can be excessive, with their levels reaching even lower than their normal baseline, placing them at a much higher risk of postpartum hemorrhage. The new NHLBI guidelines state that because coagulation factors return to pre-pregnancy levels within 14-21 days, health care providers should be in close contact with women during this period.

"While we know that decreasing VWF levels following childbirth can result in serious complications for women with VWD there are very little clinical data available to guide physicians in treating these patients," said Peter Kouides, MD, a principal investigator of the study and Medical and Research Director of the Mary M. Gooley Hemophilia Center in Rochester, NY, one of the five sites where the study will be conducted. "By studying the patterns in declining VWF levels, we hope to learn whether treatment following birth is needed and the optimum duration of therapy."

The grant will be shared among Duke University Medical Center in Durham, North Carolina, the Mary M. Gooley Hemophilia Center in Rochester, New York, Robert Wood Johnson University Hospital in New Brunswick, New Jersey and two additional study sites. Andra James, MD, of Duke University Medical Center will serve as the study's principal investigator.

Study Design

This prospect
'/>"/>

SOURCE CSL Behring Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related biology technology :

1. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
4. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
5. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
6. Siemens Receives EU Antitrust Clearance for Acquisition of Dade Behring
7. Siemens Completes Acquisition of Dade Behring
8. CSL Behring Expands Into Middle East Market with Haemate(R) P
9. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update